Valuation : Physiomics Plc

Market Cap 2.33M 3.16M 2.72M 2.56M 4.37M 298M 4.38M 30.19M 11.72M 153M 11.85M 11.59M 492M P/E 2026 *
-5.15x
P/E 2027 * -
Enterprise Value 2.07M 2.8M 2.41M 2.26M 3.87M 264M 3.88M 26.75M 10.38M 135M 10.5M 10.27M 436M EV / Sales 2026 *
2.07x
EV / Sales 2027 * -
Free-Float
74.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Physiomics Plc

1 month+10.75%
3 months-17.60%
6 months+3.00%
Current year+80.70%
1 week 0.48
Extreme 0.48
0.55
1 month 0.42
Extreme 0.42
0.55
Current year 0.25
Extreme 0.2525
0.8
1 year 0.25
Extreme 0.2525
0.8
3 years 0.25
Extreme 0.2525
3.19
5 years 0.25
Extreme 0.2525
7.25
10 years 0.25
Extreme 0.2525
32
Manager TitleAgeSince
Director of Finance/CFO 52 -
Chief Operating Officer - 2026-06-30
Corporate Officer/Principal - 2021-08-30
Director TitleAgeSince
Director/Board Member - 2026-04-28
Chairman 53 2026-04-28
Director/Board Member - 2026-04-28
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Buy

Director

3,000,000 0.6619%
7/10/26 Buy

Director

1,111,111 0.2452%
11/8/24 Buy

Chief Executive Officer

459,090 0.2259%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+15.73%-77.11% 3.16M
-1.57%+0.14%-17.91%+12.50% 133B
-5.02%-0.87%-41.75%-17.86% 48.38B
-0.29%+0.39%+2.84%+5.84% 41.78B
-6.37%-8.90%-26.41%-14.40% 22.22B
-2.44%-1.94%-35.82%-38.19% 18.28B
-2.76%+1.38%+6.99%+58.35% 17.04B
-5.93%-6.76%-10.27%-1.54% 16.27B
-3.51%-2.27%-18.27%-30.66% 11.13B
+1.69%+5.17%+4.76%+37.67% 3.53B
Average -2.62%+0.22%-12.01%-6.54% 31.14B
Weighted average by Cap. -2.65%+1.52%-18.48%+2.51%

Financials

2026 *2027 *
Net sales 1M 1.35M 1.16M 1.09M 1.87M 128M 1.88M 12.94M 5.02M 65.5M 5.08M 4.97M 211M -
Net income -314K -425K -365K -344K -587K -40.09M -589K -4.06M -1.58M -20.57M -1.59M -1.56M -66.26M -
Net Debt -266K -360K -309K -291K -498K -33.96M -499K -3.44M -1.34M -17.42M -1.35M -1.32M -56.13M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
10
Date Price Change Volume
26-09-04 GBX 0.5150 0.00% 481,192
26-09-03 GBX 0.5150 0.00% 521,126
26-09-02 GBX 0.5150 0.00% 1,199,739
26-09-01 GBX 0.5150 0.00% 555,878
26-08-28 GBX 0.5150 0.00% 870,394

Annual profits - Rate of surprise